PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.
Information regarding PGx on FDA drug labels is derived from the FDA's Table of Pharmacogenomic Biomarkers in Drug Labels. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB
The FDA recommends, but does not require, genetic testing prior to initiating or reinitiating treatment with Ticagrelor.
Excerpts from the Ticagrelor (Brilinta) drug label:
"Ticagrelor is metabolized by CYP3A4/5. Avoid use with strong CYP3A inhibitors, such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole.
...Avoid use with potent CYP3A inducers, such as rifampin, dexamethasone, phenytoin, carbamazepine, and phenobarbital.
...BRILINTA will result in higher serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg.
...Digoxin: Because of inhibition of the P-glycoprotein transporter, monitor digoxin levels with initiation of or any change in BRILINTA therapy."
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Ticagrelor drug label PDF.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.
| Position ? | Drug ? | Relevance ? |
Strength of Evidence ? |
||
|---|---|---|---|---|---|
Download a summary of all Clinical Annotations available.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.
Links in the "Drugs" column lead to PharmGKB Drug Pages.
|
Variant?
(build 132) |
Alternate Names ? | Drugs ? | Alleles ? | Function ? |
Amino Acid?
Translation |
|
|---|---|---|---|---|---|---|
| rs12333983 | A/T | Not Available | ||||
| rs12721627 | CYP3A4*16, CYP3A4*16A, CYP3A4:185 Thr>Ser, CYP3A4:554C>G, CYP3A4:658 C>G, CYP3A4:T185S, CYP3A4:Thr185Ser, c.554C>G, g.151601C>G, g.20716C>G, g.37398936G>C, g.98581C>G, p.Thr185Ser | G > C | Missense | Thr185Ser | ||
| rs12721634 | CYP3A4*14, CYP3A4:L15P, c.44T>C, g.136042T>C, g.37414504A>G, g.5148T>C, g.83013T>C, p.Leu15Pro | A > G | Missense | Leu15Pro | ||
| rs2246709 | A/G | Not Available | ||||
| rs2740574 | 5'-flanking region -392A>G, CYP3A4*1B, CYP3A4-V, CYP3A4:-392A>G, g.135607A>G, g.37414939C>T, g.4713G>A, g.82578G>A | T/C | Not Available | |||
| rs35599367 | G/A | Not Available | ||||
| rs4986907 | CYP3A4*15A, CYP3A4:589G>A, CYP3A4:Arg162Gln, CYP3A4:R162Q, c.485G>A, g.150267G>A, g.19382G>A, g.37400270C>T, g.97247G>A, p.Arg162Gln | C > T | Missense | Arg162Gln | ||
| rs4986908 | CYP3A4*10, CYP3A4:624 G>C, CYP3A4:D174H, c.520G>C, g.150302G>C, g.19417G>C, g.37400235C>G, g.97282G>C, p.Asp174His | C > G | Missense | Asp174His | ||
| rs4986909 | CYP3A4*13, CYP3A4:1351 C>T, CYP3A4:416 Pro>Leu, CYP3A4:P416L, c.1247C>T, g.105004C>T, g.158024C>T, g.27139C>T, g.37392513G>A, p.Pro416Leu | G > A | Missense | Pro416Leu | ||
| rs4986910 | 1334 C allele, 445Thr allele, CYP3A4*3, CYP3A4:M445T, c.1334T>C, g.106150T>C, g.159170T>C, g.28285T>C, g.37391367A>G, mRNA 1438T>C, p.Met445Thr | A > G | Missense | Met445Thr | ||
| rs4986913 | CYP3A4*19, CYP3A4:1503 C>T, CYP3A4:467 Pro>Ser, CYP3A4:P467S, c.1399C>T, g.106215C>T, g.159235C>T, g.28350C>T, g.37391302G>A, p.Pro467Ser | G > A | Missense | Pro467Ser | ||
| rs4987161 | CYP3A4*17, CYP3A4:189 Phe>Ser, CYP3A4:670 T>C, CYP3A4:F189S, c.566T>C, g.151613T>C, g.20728T>C, g.37398924A>G, g.98593T>C, p.Phe189Ser | A > G | Missense | Phe189Ser |
Overview
| Alternate Names: | CYPIIIA3; CYPIIIA4; P450-III, steroid inducible; albendazole monooxygenase; albendazole sulfoxidase; cytochrome P450 3A3; cytochrome P450 3A4; cytochrome P450 HLp; cytochrome P450 NF-25; cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3; cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4; cytochrome P450-PCN1; glucocorticoid-inducible P450; nifedipine oxidase; quinine 3-monooxygenase; taurochenodeoxycholate 6-alpha-hydroxylase |
|---|---|
| Alternate Symbols: | *1A; CP33; CP34; CYP3A; CYP3A3; CYP3A4*1; CYP3A4*1A; HLP; MGC126680; NF-25; P450C3; P450PCN1 |
| Haplotypes: | CYP3A4*1; CYP3A4*1A; CYP3A4*1B; CYP3A4*1C; CYP3A4*1D; CYP3A4*1E; CYP3A4*1F; CYP3A4*1G; CYP3A4*1H; CYP3A4*1J; CYP3A4*1K; CYP3A4*1L; CYP3A4*1M; CYP3A4*1N; CYP3A4*1P; CYP3A4*1Q; CYP3A4*1R; CYP3A4*1S; CYP3A4*1T; CYP3A4*2; CYP3A4*3; CYP3A4*4; CYP3A4*5; CYP3A4*6; CYP3A4*7; CYP3A4*8; CYP3A4*9; CYP3A4*10; CYP3A4*11; CYP3A4*12; CYP3A4*13; CYP3A4*14; CYP3A4*15; CYP3A4*15A; CYP3A4*15B; CYP3A4*16; CYP3A4*16A; CYP3A4*16B; CYP3A4*17; CYP3A4*18; CYP3A4*18A; CYP3A4*18B; CYP3A4*19; CYP3A4*20 |
| PharmGKB Accession Id: | PA130 |
Details
| Cytogenetic Location: | chr7 : q22.1 - q22.1 |
|---|---|
| GP mRNA Boundary†: | chr7 : 99354604 - 99381808 |
| GP Gene Boundary†: | chr7 : 99351604 - 99391808 |
| Strand: | minus |
| Product Name: | P450-III, steroid inducible, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, cytochrome P450, subfamily IIIA, polypeptide 4, glucocorticoid-inducible P450, nifedipine oxidase |
All alleles are displayed on the positive chromosomal strand.
| Haplotype | rs12721627 | rs12721629 | rs12721634 | rs2740574 | rs28371759 | rs4646438 | rs4986907 | rs4986908 | rs4986909 | rs4986910 | rs4986913 | rs4987161 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYP3A4*1 | G | G | A | T/C | A | del | C | C | G | A | G | A |
| CYP3A4*1A | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1B | G | G | A | C | A | del | C | C | G | A | G | A |
| CYP3A4*1C | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1D | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1E | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1F | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1G | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1H | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1J | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1K | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1L | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1M | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1N | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1P | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1Q | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1R | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1S | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*1T | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*2 | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*3 | G | G | A | T | A | del | C | C | G | G | G | A |
| CYP3A4*4 | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*5 | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*6 | G | G | A | T | A | T | C | C | G | A | G | A |
| CYP3A4*7 | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*8 | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*9 | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*10 | G | G | A | T | A | del | C | G | G | A | G | A |
| CYP3A4*11 | G | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*12 | G | A | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*13 | G | G | A | T | A | del | C | C | A | A | G | A |
| CYP3A4*14 | G | G | G | T | A | del | C | C | G | A | G | A |
| CYP3A4*15 | G | G | A | T/C | A | del | T | C | G | A | G | A |
| CYP3A4*15A | G | G | A | T | A | del | T | C | G | A | G | A |
| CYP3A4*15B | G | G | A | C | A | del | T | C | G | A | G | A |
| CYP3A4*16 | C | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*16A | C | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*16B | C | G | A | T | A | del | C | C | G | A | G | A |
| CYP3A4*17 | G | G | A | T | A | del | C | C | G | A | G | G |
| CYP3A4*18 | G | G | A | T | G | del | C | C | G | A | G | A |
| CYP3A4*18A | G | G | A | T | G | del | C | C | G | A | G | A |
| CYP3A4*18B | G | G | A | T | G | del | C | C | G | A | G | A |
| CYP3A4*19 | G | G | A | T | A | del | C | C | G | A | A | A |
| CYP3A4*20 | G | G | A | T | A | del | C | C | G | A | G | A |
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
-
Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics
Nateglinide metabolism and transport in liver cell.
-
Anti-diabetic Drug Repaglinide Pathway, Pharmacokinetics
Repaglinide metabolism and transport in a liver cell.
-
Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
-
Caffeine Pathway, Pharmacokinetics
Stylized liver cell showing candidate genes involved in the metabolism of caffeine.
-
Carbamazepine Pathway, Pharmacokinetics
Stylized liver cell depicting candidate genes involved in the pharmacokinetics of carbamazepine.
-
Citalopram Pathway, Pharmacokinetics
Pharmacokinetics of the selective serotonin reuptake inhibitor citalopram.
-
Clopidogrel Pathway, Pharmacokinetics
Clopidogrel metabolism.
-
Codeine and Morphine Pathway, Pharmacokinetics
Representation of the candidate genes involved in metabolism of codeine and morphine.
-
Cyclophosphamide Pathway, Pharmacokinetics
Model human liver cell showing genes involved in the metabolism of cyclophosphamide.
-
Erlotinib Pathway, Pharmacokinetics
Model human liver cell showing genes involved in the transportation and metabolism of Erlotinib.
-
Etoposide Pathway
Etoposide cellular disposition and effects.
-
Fluoxetine Pathway, Pharmacokinetics
Representation of the candidate genes involved in the metabolism of fluoxetine.
-
Fluvastatin Pathway, Pharmacokinetics
Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
-
Gefitinib Pathway (PK)
Representation of the candidate genes involved in the transportation and metabolism of gefitinib
-
Ifosfamide Pathway (PK)
Model human liver cell showing genes involved in the metabolism of ifosfamide
-
Imipramine/Desipramine Pathway, Pharmacokinetics
Representation of the candidate genes involved in the metabolism of the tricyclic antidepressants imipramine and desipramine.
-
Irinotecan Pathway, Pharmacokinetics
Model human liver cell showing blood, bile and intestinal compartments, indicating tissue specific involvement of genes in the irinotecan pathway.
-
Losartan Pathway, Pharmacokinetics
Representation of the candidate genes involved in the metabolism of losartan.
-
Phenytoin Pathway, Pharmacokinetics
Genes involved in the metabolism of phenytoin in the human liver cell.
-
Proton Pump Inhibitor Pathway, Pharmacokinetics
Omeprazole metabolism in the liver.
-
Statin Pathway - Generalized, Pharmacokinetics
Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.
-
Tamoxifen Pathway, Pharmacokinetics
Tamoxifen metabolism in the liver.
-
Taxane Pathway
Representation of the genes involved in the metabolism and transport of paclitaxel and docetaxel, and the downstream effects of the drugs
-
Vinka Alkaloid Pathway, Pharmacokinetics
Representation of the genes involved in the metabolism, transport, and downstream effects of the vinca alkaloid vincristine.
-
Warfarin Pathway, Pharmacokinetics
Representation of the candidate genes involved in transport, metabolism and clearance of warfarin.
-
Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics
Representation of candidate genes involved in the metabolism of zidovudine and its mechanism of antiviral action.
External Pathways
Links to non-PharmGKB pathways.
Datasets
- Hepatic CYP3A4 mRNA expression (Cohort III)
- Hepatic CYP3A4 Protein Expression and Midazolam Hydroxylation (Cohort II)
- Hepatic CYP3A5 predicts Saquinavir clearance
- In vivo and in vitro characterization of variants
- Intestinal CYP3A4 Protein Expression (Cohort IV)
- Intestinal Midazolam Hydroxylase Activity (Cohort V)
- Irinotecan Clinical Data
- Meperidine N-demethylation by endogenous CYP450 enzymes in human liver microsomes
- Meperidine N-demethylation by human CYP450 isoforms
- Metabolism of yohimbine by human CYP450 isoforms
- Microsomal study of midazolam, mRNA/protein levels
- Midazolam and docetaxel clearance
- mRNA expression levels of PXR splice variants in livers
- Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia
- Pharmacokinetics of etoposide, catechol metabolite
- Pharmacokinetics of irinotecan in cancer patients
- Protein expression of genes in the irinotecan pathway
- Risk of therapy-related acute myeloid leukemia
- RNA expression in metabolite and transport genes
- Tacrolimus dosing and Steroid Weaning in pediatric heart transplant patients
- Testosterone 6beta-hydroxylation Activity Induced by Rifampin (Cohort I)
- Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of CYP3A5
- A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871
- Genetic Variants in Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) associated Adverse Effects and Response to Therapy
- Genetic Variants in Statin associated Adverse Events
- P450s involved in Efavirenz Metabolism
- PHARMACOKINETICS OF ERLOTINIB and ERLOTINIB induced TOXICITY
- Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
- The Influence of CYP3A5 Expression on the Extent of Hepatic CYP3A Inhibition Is Substrate-Dependent: An in Vitro-in Vivo Evaluation
Downloads
You must sign in before you can download data.
LinkOuts
- Web Resource:
- http://www.imm.ki.se/CYPalleles/cyp3a4.htm
- UniProtKB:
- CP3A4_HUMAN (P08684)
- Q6GRK0_HUMAN (Q6GRK0)
- Ensembl:
- ENSG00000160868
- GenAtlas:
- CYP3A4
- GeneCard:
- GC07M099355 (1576)
- SOURCE:
- CYP3A4
Common Searches
Non-Curated Publications
A list of non-curated publications that mention this gene is available.